We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Doctors available 24 hours a day, 365 days a year to visit, diagnose, treat, refer and prescribe medication as needed. No membership fees or hidden costs.
days to go: Expired investment: £540,695
The Market Mogul are a Millennial media company, publishing unique perspective of the main global events in our time. They are already backed by a VC fund and have built an engaged readership and over 3000 authors. They will be using this round of funding to expand the editorial and sales teams and launch new verticals. 
days to go: Expired investment: £729,950
MODYST is a new platform where independent filmmakers can directly distribute their films to a global audience. Film lovers can watch the curated content for free and premium content for a monthly subscription fee. Modyt aims to reach 18k users and 6k premium users next year.
days to go: Expired investment: £10,720
Virtual Reality Universe provides location based virtual and augmented reality experiences.  Expensive systems and hardware requirements put such experiences out of reach for most consumers.  Virtual Reality Universe aims are to change that by placing units in busy shopping areas and sports arenas.  (SEIS Partial)
days to go: Expired investment: £57,900
Please watch the video for more information
days to go: Expired investment: £328,193
1854 Media is a multi-award-winning media brand powered by a global community of 2m+ creatives including many influential creators, media & arts institutions. It has been designed to discover and showcase the most talented, established, and emerging photographers, helping brands create imagery that cuts through the noise of 3 billion photos taken daily. Its exhibitions are seen by tens of millions with 90,000+ paid image entries. The company's mission is to become an essential platform for photographers by providing the vital tools they need to succeed. 1854 Media has 70% recurring customers since the last raise, and the company is now raising capital to accelerate growth.
days to go: Expired investment: £379,280
Ablatus Therapeutics is a MedTech company developing a one-of-a-kind tissue ablation platform known as Bimodal Electric Tissue Ablation (BETA). This technology has been designed to overcome the limitations of existing products by offering ablation solutions in oncology (tumours) as well as non-oncology targets. With the proceeds, the company will finish the final elements of engineering of the generator and probe. It will also deliver formal safety test data that is a prerequisite for subsequent clinical trials.
days to go: Expired investment: Withheld
Active Needle is a medical device company that aims to prevent the problem of needle placement errors in ultrasound-guided needle interventional procedures. The technology allows for precision needle targeting.
days to go: Expired investment: £147,514
Amplify Music, in association with the Music Managers Forum (MMF), provides UK tax paying investors with the opportunity to invest in the future careers of new and emerging music artists while benefiting from the significant tax advantages available through SEIS. MMF was established in 1992 and is now the largest representative body of artist managers in the world. MMF has over 400 members in the UK and represents over 1,000 of the world’s most successful acts.
days to go: Expired investment: Withheld
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
days to go: Expired investment: Withheld
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph